Free Trial
NASDAQ:ANEB

Anebulo Pharmaceuticals Q3 2024 Earnings Report

Anebulo Pharmaceuticals logo
$2.52 -0.09 (-3.45%)
Closing price 08/28/2025 03:57 PM Eastern
Extended Trading
$2.52 +0.00 (+0.20%)
As of 08/28/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Anebulo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anebulo Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
4:30PM ET

Upcoming Earnings

Anebulo Pharmaceuticals' Q4 2025 earnings is scheduled for Wednesday, September 24, 2025, with a conference call scheduled on Monday, September 22, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Anebulo Pharmaceuticals Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Anebulo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (NASDAQ:ANEB), a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

View Anebulo Pharmaceuticals Profile

More Earnings Resources from MarketBeat